Trial Profile
A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Ichorcumab (Primary) ; Apixaban
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms TEXT-TKR
- Sponsors Janssen Research & Development
- 30 Jul 2022 This trial has been discontinued in Romania (Date of the global end of the trial : 05-Nov-2018), according to European Clinical Trials Database record.
- 16 Sep 2019 Results (n=239) safety and efficacy of JNJ-9375 with apixban in prevention of venous thrombosis, published in the Journal of Thrombosis and Haemostasis.
- 18 Mar 2019 Results presented at the 68th Annual Scientific Session of the American College of Cardiology